Suppr超能文献

用磷霉素验证针对大肠杆菌和铜绿假单胞菌的突变选择窗假说:一项体外和体内比较研究。

Validation of the mutant selection window hypothesis with fosfomycin against Escherichia coli and Pseudomonas aeruginosa: an in vitro and in vivo comparative study.

作者信息

Pan Ai-Jun, Mei Qing, Ye Ying, Li Hong-Ru, Liu Bao, Li Jia-Bin

机构信息

Department of Infectious Diseases, First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.

Department of Critical Care Medicine, Affiliated Provincial Hospital of Anhui Medical University, Hefei, Anhui, China.

出版信息

J Antibiot (Tokyo). 2017 Feb;70(2):166-173. doi: 10.1038/ja.2016.124. Epub 2016 Oct 19.

Abstract

The purpose of this study was to validate the mutant selection window (MSW) hypothesis in vitro and in vivo with Escherichia coli and Pseudomonas aeruginosa exposed to fosfomycin. Two standard strains of Gram-negative bacteria, those are E. coli ATCC 25922 and P. aeruginosa ATCC 27853, were exposed to fosfomycin at concentrations below MIC, between the MIC and the mutant prevention concentration (MPC), and above the MPC in Luria-Bertani broth and in a tissue-cage infection model, respectively. With the in vitro time-kill studies, there were bacterial re-growth and emergence of resistance thereafter for both strains at antibiotic concentrations of × 4, × 8 and × 16 MIC. In our animal model, the loss in susceptibility of P. aeruginosa at fosfomycin concentrations fluctuated between the lower and upper boundaries of the MSW. In contrast, the emergence of resistant mutants of E. coli was not observed in vivo, regardless of fosfomycin dosage. Interestingly, the in vitro-isolated resistant mutants of E. coli showed a decreased growth rate compared with the susceptible parental strains, whereas no fitness cost in P. aeruginosa was observed. The emergence of antibiotic resistance is shaped by several factors. MSW theory may not apply to all antimicrobial-pathogen combinations. Before it can be used as a framework for the design of antimicrobial therapy, the existence of the window must be demonstrated not only in vitro but also in vivo.

摘要

本研究的目的是在体外和体内验证突变选择窗(MSW)假说,以大肠杆菌和铜绿假单胞菌作为受试菌株,使其暴露于磷霉素中。分别在Luria-Bertani肉汤和组织笼感染模型中,将两种革兰氏阴性菌标准菌株,即大肠杆菌ATCC 25922和铜绿假单胞菌ATCC 27853,暴露于低于最低抑菌浓度(MIC)、介于MIC和突变预防浓度(MPC)之间以及高于MPC的磷霉素浓度下。通过体外时间杀菌研究,在抗生素浓度为4倍、8倍和16倍MIC时,两种菌株均出现了细菌再生长及随后的耐药性产生。在我们的动物模型中,铜绿假单胞菌在磷霉素浓度处于MSW上下限之间波动时出现了敏感性丧失。相比之下,无论磷霉素剂量如何,在体内均未观察到大肠杆菌耐药突变体的出现。有趣的是,体外分离的大肠杆菌耐药突变体与敏感亲代菌株相比生长速率降低,而未观察到铜绿假单胞菌存在适应性代价。抗生素耐药性的产生受多种因素影响。MSW理论可能并不适用于所有抗菌药物-病原体组合。在其能够作为抗菌治疗设计的框架之前,不仅必须在体外而且要在体内证明该窗口的存在。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验